Teladoc Health, Inc.
Teladoc Health, Inc. (0LDR.L) Financial Performance & Income Statement Overview
Review Teladoc Health, Inc. (0LDR.L) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Teladoc Health, Inc. (0LDR.L) Income Statement & Financial Overview
Explore comprehensive income reports for Teladoc Health, Inc. 0LDR.L, broken down by year and quarter.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $629.37M | $640.49M | $640.51M | $642.44M |
| Cost of Revenue | $196.83M | $188.93M | $179.75M | $284.62M |
| Gross Profit | $432.54M | $451.56M | $460.76M | $357.82M |
| Gross Profit Ratio | $0.69 | $0.71 | $0.72 | $0.56 |
| R&D Expenses | $69.96M | $76.75M | $72.38M | $76.75M |
| SG&A Expenses | $280.96M | $274.72M | $339.17M | $330.26M |
| Operating Expenses | $553.15M | $499.78M | $505.16M | $407.01M |
| Total Costs & Expenses | $749.98M | $688.71M | $684.91M | $691.63M |
| Interest Income | $12.67M | $14.23M | $15.33M | $13.57M |
| Interest Expense | $5.76M | $6.85M | $5.66M | $5.65M |
| Depreciation & Amortization | -$15.11M | $91.67M | $91.81M | $98.85M |
| EBITDA | -$120.61M | $50.35M | $64.98M | -$729.29M |
| EBITDA Ratio | -$0.19 | $0.08 | $0.10 | -$1.14 |
| Operating Income | -$120.61M | -$48.22M | -$44.40M | -$49.19M |
| Operating Income Ratio | -$0.19 | -$0.08 | -$0.07 | -$0.08 |
| Other Income/Expenses (Net) | $9.34M | $44000.00 | $11.90M | $7.36M |
| Income Before Tax | -$111.27M | -$48.17M | -$32.50M | -$833.79M |
| Income Before Tax Ratio | -$0.18 | -$0.08 | -$0.05 | -$1.30 |
| Income Tax Expense | -$18.25M | $238000.00 | $780000.00 | $3.88M |
| Net Income | -$93.01M | -$48.41M | -$33.28M | -$837.67M |
| Net Income Ratio | -$0.15 | -$0.08 | -$0.05 | -$1.30 |
| EPS | -$0.53 | -$0.28 | -$0.20 | -$4.92 |
| Diluted EPS | -$0.53 | -$0.28 | -$0.19 | -$4.92 |
| Weighted Avg Shares Outstanding | $174.15M | $172.77M | $170.23M | $170.23M |
| Weighted Avg Shares Outstanding (Diluted) | $174.15M | $172.77M | $171.50M | $170.23M |
Over the last four quarters, Teladoc Health, Inc.'s revenue moved from $642.44M in Q2 2024 to $629.37M in Q1 2025. Operating income in Q1 2025 was -$120.61M, with a strong operating margin of -19%. Despite fluctuations in R&D and SG&A expenses, EBITDA for Teladoc Health, Inc. remained robust at -$120.61M, reflecting operational efficiency. Net income dropped to -$93.01M, with an EPS of -$0.53. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan